Processa Pharmaceuticals Announces Second Quarter 2021 Results and Provides Corporate Update
12 août 2021 17h15 HE
|
Processa Pharmaceuticals, Inc.
Adds fourth clinical asset, RX-3117, and targets major milestones in the second half of 2021 HANOVER, Md., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a...
Processa Pharmaceuticals to Present at “Zooming with LD Micro” Virtual Investor Event on July 29, 2021 at 12:00 p.m. ET
27 juil. 2021 08h30 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, July 27, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) announced today that it will be presenting at the upcoming “Zooming with LD Micro” virtual investor event...
Processa Pharmaceuticals to Present at LD Micro Virtual Investor Conference on June 9, 2021, at 1:30pm ET
07 juin 2021 16h05 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, June 07, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve...
Processa Pharmaceuticals Announces First Patient Dosed in its Randomized Double-Blind, Placebo-Controlled Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica
20 mai 2021 16h05 HE
|
Processa Pharmaceuticals, Inc.
~Processa’s trial is currently enrolling patients with ulcerated Necrobiosis Lipoidica. Detailed information on the trial can be located on clinicaltrials.gov NCT#: 04800562.~ HANOVER, MD., May 20,...
Processa Pharmaceuticals to Participate in Upcoming Investor Conferences
18 mai 2021 16h05 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD., May 18, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve...
Processa Pharmaceuticals Announces Year end 2020 Results and Provides Corporate Update
25 mars 2021 16h06 HE
|
Processa Pharmaceuticals, Inc.
Clinical drug pipeline is funded and targeting major milestones in 2021 HANOVER, Md., March 25, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"),...
Processa Pharmaceuticals Schedules Conference Call to Discuss Fourth Quarter Results and Provide Drug Development Update on March 25 at 5:30 p.m. ET
22 mars 2021 09h15 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD., March 22, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to...
Processa Announces Sites Selected for Phase 2B Clinical Trial to Treat Patients with Ulcerated Necrobiosis Lipoidica
17 mars 2021 09h15 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, March 17, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical stage company developing drugs for patients who have unmet medical...
Processa Pharmaceuticals Announces Closing of a $10.2 Million Private Placement
02 mars 2021 09h15 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, March 02, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) is pleased to announce it has closed its previously announced private placement to institutional and...
Processa Pharmaceuticals to Present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference
11 janv. 2021 10h50 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to...